Journal of Diagnostics Concepts & Practice >
Automated synthesis of dopamine transporters imaging probe 18F-FP-CIT based on allin one for Micro PET/CT imaging of rat basal ganglia
Received date: 2022-02-20
Online published: 2022-11-07
Objective: To verify the efficiency and stability of the automated labeling and synthesis of dopamine transporters (DAT) imaging probe, 18F-N-(3-fluoropropyl)-2β-carbomethoxy-3β-(4′-iodophenyl) nortropane (18F-FP-CIT), based on the AllinOne module. Meanwhile, to evaluate the safety and targeted ability of the probe and the imaging effect on the basal ganglia of rats. Methods: A fluorination reaction between nitrogen-[3-(methoxy)propyl]-2β-carbonmethoxy-3β-(4′-iodophenyl) nortropane, the reaction precursor, and the dried fluorine-18 ion (18F) was performed, under the catalysis of TBAOH and Kryptofix 222. The product of the reaction was separated and purified by high performance liquid chromatography (HPLC). All the procedure was established on the AllinOne module under the highest yield conditions to perform automated labeling and synthesis of 18F-FP-CIT. Quality control tests and Micro PET/CT imaging of rat brain with the automatically synthesized product were carried out. Results: The average synthesis time, efficiency after attenuation correction, and radiochemical purity of 20 batches of 18F-FP-CIT made by the AllinOne module was (72.9±8.9) min, 34.8%±5.7%, and 98.4%±2.0%, retrospectively. The results of sterility test, endotoxin test, toxicity test and residual solvent test of acetonitrile were all met the clinical practice standards. Micro PET/CT imaging showed uniform and obvious targeted uptake of 18F-FP-CIT in basal ganglia of normal rats, and the uptake of 18F-FP-CIT in basal ganglia was 2.6 times that in cerebral cortex, 3.7 times that in cerebellum, and 4.1 times that in skull, respectively. Conclusions: The AllinOne module can automatically label and synthesize DAT imaging probe 18F-FP-CIT stably, rapidly, with high-quality, which is expected to provide imaging technical support for the clinical diagnosis and treatment of neurodegenerative changes such as Parkinson′s disease (PD).
QU Qian, HAI Wangxi, HU Shengyan, ZHANG Min, CHEN Xiaoyue, ZHOU Yilei, WANG Jin, HU Xiaoping, LI Biao, HU Jiajia . Automated synthesis of dopamine transporters imaging probe 18F-FP-CIT based on allin one for Micro PET/CT imaging of rat basal ganglia[J]. Journal of Diagnostics Concepts & Practice, 2022 , 21(04) : 482 -489 . DOI: 10.16150/j.1671-2870.2022.04.011
[1] | Poewe W, Seppi K, Tanner CM, et al. Parkinson disease[J]. Nat Rev Dis Primers, 2017, 3:17013. |
[2] | Li G, Ma J, Cui S, et al. Parkinson′s disease in China: a forty-year growing track of bedside work[J]. Transl Neurodegener, 2019, 8:22. |
[3] | 黄丽芬, 邓子德, 叶晓新, 等. 345例艾滋病死亡病例的医院感染状况分析[J]. 中国感染控制杂志, 2013, 12(3):178-181. |
[3] | Deng ZD, Ye XX, et al. Healthcare-associated infection in 345 HIV/AIDS death cases[J]. Chin J Infect Control, 2013, 12(3):178-181. |
[4] | Niznik HB, Fogel EF, Fassos FF, et al. The dopamine transporter is absent in parkinsonian putamen and reduced in the caudate nucleus[J]. J Neurochem, 1991, 56(1):192-198. |
[5] | Kaufman MJ, Madras BK. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson′s-diseased striatum[J]. Synapse, 1991, 9(1):43-49. |
[6] | Marshall V, Grosset D. Role of dopamine transporter imaging in routine clinical practice[J]. Mov Disord, 2003, 18(12):1415-1423. |
[7] | McHugh PC, Buckley DA. The structure and function of the dopamine transporter and its role in CNS diseases[J]. Vitam Horm, 2015, 98:339-369. |
[8] | Rispoli V, Schreglmann SR, Bhatia KP. Neuroimaging advances in Parkinson′s disease[J]. Curr Opin Neurol, 2018, 31(4):415-424. |
[9] | Ikeda K, Ebina J, Kawabe K, et al. Dopamine transporter imaging in parkinson disease: progressive changes and therapeutic modification after anti-parkinsonian medications[J]. Intern Med, 2019, 58(12):1665-1672. |
[10] | Lee SJ, Oh SJ, Chi DY, et al. One-step high-radiochemical-yield synthesis of [18F]FP-CIT using a protic solvent system[J]. Nucl Med Biol, 2007, 34(4):345-351. |
[11] | Booij J, Tissingh G, Boer GJ, et al. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson′s di-sease[J]. J Neurol Neurosurg Psychiatry, 1997, 62(2):133-140. |
[12] | Bajaj N, Hauser RA, Grachev ID. Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes[J]. J Neurol Neurosurg Psychiatry, 2013, 84(11):1288-1295. |
[13] | Palermo G, Giannoni S, Bellini G, et al. Dopamine transporter imaging, current status of a potential biomarker: a comprehensive review[J]. Int J Mol Sci, 2021, 22(20):11234. |
[14] | Chaly T, Dhawan V, Kazumata K, et al. Radiosynthesis of [18F] N-3-fluoropropyl-2-beta-carbomethoxy-3-beta-(4-iodophenyl) nortropane and the first human study with positron emission tomography[J]. Nucl Med Biol, 1996, 23(8):999-1004. |
[15] | Leung K. N-(3-[(18)F]Fluoropropyl)-2β-carbomethoxy-3β-(4-iodophenyl)nortropane[M]. Molecular Imaging and Contrast Agent Database (MICAD). Bethesda (MD): National Center for Biotechnology Information (US), 2004. |
[16] | Hong CM, Ryu HS, Ahn BC. Early perfusion and dopamine transporter imaging using 18F-FP-CIT PET/CT in patients with parkinsonism[J]. Am J Nucl Med Mol Imaging, 2018, 8(6):360-372. |
[17] | Park HK, Kim JS, Im KC, et al. Functional brain imaging in pure akinesia with gait freezing: [18F] FDG PET and [18F] FP-CIT PET analyses[J]. Mov Disord, 2009, 24(2):237-245. |
[18] | 陈正平, 吴春英, 张政伟, 等. 多巴胺转运蛋白显像剂18F-FP-β-CIT制备与分布[J]. 中华核医学杂志, 2003, 23(4):241-243. |
[18] | Chen ZP, Wu CY, Zhang ZW, et al. Preparation of a dopamine transporter imaging agent 18F-FP-β-CIT and its biodistribution in rat brain[J]. Chin J Nuc Med & Mol Imaging, 2003, 23(4):241-243. |
[19] | Lee SJ, Oh SJ, Moon WY, et al. New automated synthesis of [18F]FP-CIT with base amount control affording high and stable radiochemical yield: a 1.5-year production report[J]. Nucl Med Biol, 2011, 38(4):593-597. |
[20] | 张晓懿, 朱静, 沈超, 等. 多巴胺转运体显像剂18F-FPCIT的合成与microPET显像[J]. 医药前沿, 2017, 7(36):50-52. |
[20] | Zhang XY, Zhu J, Shen C, et al. Synthesis of dopamine transporter imaging agent 18F-FPCIT and its microPET imaging[J]. J Front Med, 2017, 7(36):50-52. |
[21] | 戴红峰. Tracerlab FX-FN化学合成模块液相转移故障探讨[J]. 化学工程与装备, 2018(10):39-40,63. |
[21] | Dai HF. Discussion on liquid phase transfer fault of tra-cerlab FX-FN chemical synthesis module[J]. Fujian Chem Ind, 2018(10):39-40,63. |
[22] | Vala C, Mothes C, Chicheri G, et al. Fully automated radiosynthesis of [18F]LBT999 on TRACERlab FX FN and AllinOne modules, a PET radiopharmaceutical for ima-ging the dopamine transporter in human brain[J]. EJNMMI Radiopharm Chem, 2020, 5(1):26. |
[23] | 国家药典委员会. 中华人民共和国药典(第四部)[M]. 北京: 中国医药科技出版社, 2020. |
[23] | National Pharmacopoeia Commission. Pharmacopoeia of the People′s Republic of China (the Fourth Part)[M]. Beijing: China Medical Science and Technology Press, 2020. |
[24] | Hung JC. Comparison of various requirements of the quality assurance procedures for (18)F-FDG injection[J]. J Nucl Med, 2002, 43(11):1495-1506. |
/
〈 |
|
〉 |